Key result
High dose aspirin >6 months post-PED was associated with fewer permanent thrombotic and hemorrhagic events, while platelet function testing showed no significant association with symptomatic events.
Why the study?
Does antiplatelet therapy dose, duration, and platelet function testing affect hemorrhagic and thrombotic complications in patients with cerebral aneurysms treated with the pipeline embolization device?
Population
Patients with cerebral aneurysms treated with the pipeline embolization device from 19 single and…
Comparison
Antiplatelet therapy including aspirin dose… vs Different APT doses, durations, and regimens.
Design
Meta-analysis
Authors
Loading...
High-dose aspirin >6 months post-PED may reduce events; supports extended duration while challenging platelet function testing.
Meta-Analysis
Yes
Does antiplatelet therapy dose, duration, and platelet function testing affect hemorrhagic and thrombotic complications in patients with cerebral aneurysms treated with the pipeline embolization device?
In patients treated with the pipeline embolization device for cerebral aneurysms, high-dose aspirin for >6 months and loading doses of dual antiplatelet therapy are associated with fewer complications, whereas platelet function testing has no significant impact.
Skukalek et al. (2014) conducted a meta-analysis in Cerebral aneurysms. Antiplatelet therapy and platelet function testing vs. Alternative antiplatelet regimens was evaluated on Hemorrhagic or thrombotic complications. High dose aspirin >6 months post-PED was associated with fewer permanent thrombotic and hemorrhagic events, while platelet function testing showed no significant association with symptomatic events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: